Phone: 1-647-923-2770
Margaret Hux, MSc.

Health Economics and Health Technology
Research Consulting

 
Marg@MargaretHux.ca
 

Supporting Market Access for Medications and other Health Technologies

Experience

Professional Experience:

2015 to 2017

  • IMS Health Brogan / Quintiles IMS, Mississauga, ON
    Health Economics Lead

2011 to 2015

  • Oxford Outcomes, Toronto, ON (now ICON Research)
    Director, Health Economics

1999 to 2011

  • Innovus Research Inc. (INNOVUS), Burlington, ON
    • Associate Director, Health Economics & Epidemiology
    • Senior Manager, Health Economics & Epidemiology
    • Clinical Research Associate

Education

  • M.Sc. in Biostatistics & Epidemiology
    McMaster University, Hamilton, Ontario
  • Emotional Success Coach,
    Certified Accredited EFT Practitioner, National EFT Training Institute,  www.NeftTI.com and EFT International
  • Spiritual Psychotherapy and Spiritual Director  (in process)
    Transformational Arts College, Toronto, Ontario 
    https://transformationalarts.com/

Research Interests:

  • Innovative health technologies such as emotional freedom techniques or other energy medicine interventions.
     
  • Health economics and market access research for medications, medical devices and health interventions. Therapeutic areas include oncology, cardiology, Alzheimer’s disease, infectious disease, wound care.
     
  • Concurrent economic evaluation within clinical trials including country-specific evaluations from multinational trials.
     
  • Modeling studies have used excel-based models with partitioned survival or Markov, including probabilistic sensitivity analyses. Model adaptations to Canada have been conducted for many indications.
     
  • Assessment of quality of life and health state utility, patient reported outcome plans for trial design, as well as web-based collection of data to allow utility estimation.
     
  • Patient surveys and chart reviews have been conducted in oncology (infection post chemotherapy, prophylaxis against infection post chemotherapy, myelodysplastic syndromes)